Insmed (INSM) - 41.72% Below 52-Week High: Buy or Wait?

Stock Details

Insmed Incorporated (INSM), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $124.00. Over the past 52 weeks, it has ranged between $90.39 and $212.75. This places the current price at 58.3% of its 52-week high and 37.2% above its 52-week low. Recent trading volume was recorded at 2,373,321. The 14-day Relative Strength Index (RSI) stands at 55.77, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $111.87 by 10.84%. Similarly, it is below its 200-day moving average of $143.57 by 13.63%. The MACD histogram is -0.39, indicating bearish momentum (MACD Line: 4.58, Signal Line: 4.98).

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

154.43

PEG Ratio

1.09

Reasonably valued

Price to Book

35.70

EV/EBITDA

-33.51

EPS (TTM)

-$4.12

Price to Sales

23.78

Beta

0.79

Less volatile than market

Q:How is INSM valued relative to its earnings and growth?

Valuation data is not available for this stock.

Q:What is INSM's risk profile compared to the market?

With a beta of 0.79, Insmed Incorporated is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 35.70 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-76.94%

Operating Margin

-23.81%

EBITDA

$-794,955,008

Return on Equity

-87.22%

Return on Assets

-22.17%

Revenue Growth (YoY)

296.10%

Q:How profitable and efficient is INSM's business model?

Insmed Incorporated achieves a profit margin of -76.94%, meaning it retains $-76.94 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -23.81% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -87.22% and ROA at -22.17%, the company achieves moderate returns on invested capital.

Q:What are INSM's recent growth trends?

Insmed Incorporated's revenue grew by 296.10% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$27.1B

Revenue (TTM)

$1.14B

Revenue/Share (TTM)

$5.30

Shares Outstanding

218.38M

Book Value/Share

$3.47

Asset Type

EQUITY

Q:What is INSM's market capitalization and position?

Insmed Incorporated has a market capitalization of $27.1B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 218.38M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.

Q:How does INSM's price compare to its book value?

Insmed Incorporated's book value per share is $3.47, while the current stock price is $124.00, resulting in a price-to-book (P/B) ratio of 35.73. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$200.18

61.44% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

Q:How reliable are analyst predictions for INSM?

19 analysts cover INSM with 95% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $200.18 implies 61.4% upside, but targets are often adjusted to follow price moves rather than predict them.

Q:What is the Wall Street consensus on INSM?

Current analyst recommendations:1 Strong Buy, 17 Buy, 1 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Aug 26, 2026, 02:21 AM

Technical Indicators

RSI (14-day)

55.77

Neutral

50-Day Moving Average

$111.87

10.84% above MA-50

200-Day Moving Average

$143.57

-13.63% below MA-200

MACD Line

4.58

MACD Signal

4.98

MACD Histogram

-0.39

Bearish

Q:What does INSM's RSI value tell investors?

The RSI (Relative Strength Index) for INSM is currently 55.77, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being above the 50-day moving average, this confirms bullish conditions.

Q:How should traders interpret INSM's MACD and moving average crossovers?

MACD analysis shows the MACD line at 4.58 below the signal line at 4.98, with histogram at -0.39. This bearish crossover indicates downward pressure. The 50-day MA ($111.87) is below the 200-day MA ($143.57), forming a death cross pattern that often warns of extended weakness. Price is currently between the MAs, suggesting transition.

Indicators last updated: Aug 26, 2026, 01:03 AM

Insmed Incorporated (INSM) Stock